The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Enhanced neonatal Fc receptor function improves protection against primate SHIV infection
Open accessAbstract
To protect against human immunodeficiency virus (HIV-1) infection, broadly neutralizing antibodies (bnAbs) must be active at the portals of viral entry in the gastrointestinal or cervicovaginal tracts. The localization and persistence of antibodies at these sites is influenced by the neonatal Fc receptor (FcRn), whose role in protecting against infection in vivo has not been defined. Here, we show that a bnAb with enhanced FcRn binding has increased gut mucosal tissue localization, which improves protection against lentiviral infection in non-human primates. A bnAb directed to the CD4-binding site of the HIV-1 envelope (Env) protein (denoted VRC01) was modified by site-directed mutagenesis to increase its binding affinity for FcRn. This enhanced FcRn-binding mutant bnAb, denoted VRC01-LS, displayed increased transcytosis across human FcRn-expressing cellular monolayers in vitro while retaining FcγRIIIa binding and function, including antibody-dependent cell-mediated cytotoxicity (ADCC) activity, at levels similar to VRC01 (the wild type). VRC01-LS had a threefold longer serum half-life than VRC01 in non-human primates and persisted in the rectal mucosa even when it was no longer detectable in the serum. Notably, VRC01-LS mediated protection superior to that afforded by VRC01 against intrarectal infection with simian–human immunodeficiency virus (SHIV). These findings suggest that modification of FcRn binding provides a mechanism not only to increase serum half-life but also to enhance mucosal localization that confers immune protection. Mutations that enhance FcRn function could therefore increase the potency and durability of passive immunization strategies to prevent HIV-1 infection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fcγ receptors as regulators of immune responses
Nimmerjahn, F., & Ravetch, J. V. (2008) · Nature Reviews Immunology · doi:10.1038/nri2206 · Cited by 2,947
FcRn: the neonatal Fc receptor comes of age
Roopenian, D. C., & Akilesh, S. (2007) · Nature Reviews Immunology · doi:10.1038/nri2155 · Cited by 2,346
Keele, B. F., Giorgi, E. E., Salazar-Gonzalez, J. F., Decker, J. M., Pham, K. T., Salazar, M. G., Sun, C., Grayson, T., Wang, S., Li, H., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0802203105 · Cited by 1,912
Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1
Wu, X., Yang, Z.-Y., Li, Y., Hogerkorp, C.-M., Schief, W. R., Seaman, M. S., Zhou, T., Schmidt, S. D., Wu, L., Xu, L., et al. (2010) · Science · doi:10.1126/science.1187659 · Cited by 1,730
Self-citationBroad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target
Walker, L. M., Phogat, S. K., Chan-Hui, P.-Y., Wagner, D., Phung, P., Goss, J. L., Wrin, T., Simek, M. D., Fling, S., Mitcham, J. L., et al. (2009) · Science · doi:10.1126/science.1178746 · Cited by 1,723
Broad neutralization coverage of HIV by multiple highly potent antibodies
Walker, L. M., Huber, M., Doores, K. J., Falkowska, E., Pejchal, R., Julien, J.-P., Wang, S.-K., Ramos, A., Chan-Hui, P.-Y., Moyle, M., et al. (2011) · Nature · doi:10.1038/nature10373 · Cited by 1,480
Li, M., Gao, F., Mascola, J. R., Stamatatos, L., Polonis, V. R., Koutsoukos, M., Voss, G., Goepfert, P., Gilbert, P., Greene, K. M., et al. (2005) · Journal of Virology · doi:10.1128/jvi.79.16.10108-10125.2005 · Cited by 1,070
Self-citationFc receptor but not complement binding is important in antibody protection against HIV
Hessell, A. J., Hangartner, L., Hunter, M., Havenith, C. E. G., Beurskens, F. J., Bakker, J. M., Lanigan, C. M. S., Landucci, G., Forthal, D. N., Parren, P. W. H. I., et al. (2007) · Nature · doi:10.1038/nature06106 · Cited by 901
THE COVALENT STRUCTURE OF AN ENTIRE γG IMMUNOGLOBULIN MOLECULE
Edelman, G. M., Cunningham, B. A., Gall, W. E., Gottlieb, P. D., Rutishauser, U., & Waxdal, M. J. (1969) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.63.1.78 · Cited by 901
Broad and potent neutralization of HIV-1 by a gp41-specific human antibody
Huang, J., Ofek, G., Laub, L., Louder, M. K., Doria-Rose, N. A., Longo, N. S., Imamichi, H., Bailer, R. T., Chakrabarti, B., Sharma, S. K., et al. (2012) · Nature · doi:10.1038/nature11544 · Cited by 828
Self-citationEnhanced antibody half-life improves in vivo activity
Zalevsky, J., Chamberlain, A. K., Horton, H. M., Karki, S., Leung, I. W. L., Sproule, T. J., Lazar, G. A., Roopenian, D. C., & Desjarlais, J. R. (2010) · Nature Biotechnology · doi:10.1038/nbt.1601 · Cited by 653
Properties of Human IgG1s Engineered for Enhanced Binding to the Neonatal Fc Receptor (FcRn)
Dall'Acqua, W. F., Kiener, P. A., & Wu, H. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m604292200 · Cited by 646
Seaman, M. S., Janes, H., Hawkins, N., Grandpre, L. E., Devoy, C., Giri, A., Coffey, R. T., Harris, L., Wood, B., Daniels, M. G., et al. (2010) · Journal of Virology · doi:10.1128/jvi.02108-09 · Cited by 632
Self-citationHessell, A. J., Rakasz, E. G., Poignard, P., Hangartner, L., Landucci, G., Forthal, D. N., Koff, W. C., Watkins, D. I., & Burton, D. R. (2009) · PLoS Pathogens · doi:10.1371/journal.ppat.1000433 · Cited by 497
Yoshida, M., Claypool, S. M., Wagner, J. S., Mizoguchi, E., Mizoguchi, A., Roopenian, D. C., Lencer, W. I., & Blumberg, R. S. (2004) · Immunity · doi:10.1016/j.immuni.2004.05.007 · Cited by 471
Self-citationMoldt, B., Rakasz, E. G., Schultz, N., Chan-Hui, P.-Y., Swiderek, K., Weisgrau, K. L., Piaskowski, S. M., Bergman, Z., Watkins, D. I., Poignard, P., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1214785109 · Cited by 463
Roopenian, D. C., Christianson, G. J., Sproule, T. J., Brown, A. C., Akilesh, S., Jung, N., Petkova, S., Avanessian, L., Choi, E. Y., Shaffer, D. J., et al. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.7.3528 · Cited by 456
Increasing the Affinity of a Human IgG1 for the Neonatal Fc Receptor: Biological Consequences
Acqua, W. F. D., Woods, R. M., Ward, E. S., Palaszynski, S. R., Patel, N. K., Brewah, Y. A., Wu, H., Kiener, P. A., & Langermann, S. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.9.5171 · Cited by 368
Robbie, G. J., Criste, R., Dall'Acqua, W. F., Jensen, K., Patel, N. K., Losonsky, G. A., & Griffin, M. P. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01285-13 · Cited by 366
Broadly neutralizing antibodies and the search for an HIV-1 vaccine: the end of the beginning
Kwong, P. D., Mascola, J. R., & Nabel, G. J. (2013) · Nature Reviews Immunology · doi:10.1038/nri3516 · Cited by 329
Self-citationPetkova, S. B., Akilesh, S., Sproule, T. J., Christianson, G. J., Al Khabbaz, H., Brown, A. C., Presta, L. G., Meng, Y. G., & Roopenian, D. C. (2006) · International Immunology · doi:10.1093/intimm/dxl110 · Cited by 314
Cumulative mechanisms of lymphoid tissue fibrosis and T cell depletion in HIV-1 and SIV infections
Zeng, M., Smith, A. J., Wietgrefe, S. W., Southern, P. J., Schacker, T. W., Reilly, C. S., Estes, J. D., Burton, G. F., Silvestri, G., Lifson, J. D., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45157 · Cited by 309
Self-citationAn Engineered Human IgG1 Antibody with Longer Serum Half-Life
Hinton, P. R., Xiong, J. M., Johlfs, M. G., Tang, M. T., Keller, S., & Tsurushita, N. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.1.346 · Cited by 282
Mucosal Immunity Induced by Enhanced-Potency Inactivated and Oral Polio Vaccines
Onorato, I. M., Modlin, J. F., McBean, A. M., Thoms, M. L., Losonsky, G. A., & Bernier, R. H. (1991) · Journal of Infectious Diseases · doi:10.1093/infdis/163.1.1 · Cited by 246
Pegu, A., Yang, Z.-Y., Boyington, J. C., Wu, L., Ko, S.-Y., Schmidt, S. D., McKee, K., Kong, W.-P., Shi, W., Chen, X., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008992 · Cited by 242
Self-citationBitonti, A. J., Dumont, J. A., Low, S. C., Peters, R. T., Kropp, K. E., Palombella, V. J., Stattel, J. M., Lu, Y., Tan, C. A., Song, J. J., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0403235101 · Cited by 233
Self-citationLi, Z., Palaniyandi, S., Zeng, R., Tuo, W., Roopenian, D. C., & Zhu, X. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1012861108 · Cited by 224
Poliovirus type 1 enters the human host through intestinal M cells
Siciński, P., Rowiński, J., Warchoł, J. B., Jarząbek, Z., Gut, W., Szczygieł, B., Bielecki, K., & Koch, G. (1990) · Gastroenterology · doi:10.1016/0016-5085(90)91290-m · Cited by 216
Gómez-Román, V. R., Florese, R. H., Patterson, L. J., Peng, B., Venzon, D., Aldrich, K., & Robert-Guroff, M. (2006) · Journal of Immunological Methods · doi:10.1016/j.jim.2005.09.018 · Cited by 202
Chapter 4 Multitasking by Exploitation of Intracellular Transport Functions
Ward, E. S., & Ober, R. J. (2009) · Advances in immunology · doi:10.1016/s0065-2776(09)03004-1 · Cited by 176
Baker, K., Räth, T., Flak, M. B., Arthur, J. C., Chen, Z., Glickman, J. N., Zlobec, I., Karamitopoulou, E., Stachler, M. D., Odze, R. D., et al. (2013) · Immunity · doi:10.1016/j.immuni.2013.11.003 · Cited by 146
Self-citationSmalls-Mantey, A., Doria‐Rose, N. A., Klein, R. M., Patamawenu, A. A., Migueles, S. A., Ko, S., Hallahan, C. W., Wong, H. C., Liu, B., You, L., et al. (2012) · Journal of Virology · doi:10.1128/jvi.00287-12 · Cited by 110
Self-citationClaypool, S. M., Dickinson, B. L., Yoshida, M., Lencer, W. I., & Blumberg, R. S. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202367200 · Cited by 107
Self-citationGastinel, L. N., Simister, N. E., & Björkman, P. J. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.2.638 · Cited by 98
Shu, Y., Winfrey, S., Yang, Z., Xu, L., Rao, S. S., Srivastava, I. K., Barnett, S. W., Nabel, G. J., & Mascola, J. R. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.10.046 · Cited by 76
Self-citationKlein, K., Veazey, R. S., Warrier, R., Hraber, P., Doyle‐Meyers, L. A., Buffa, V., Liao, H., Haynes, B. F., Shaw, G. M., & Shattock, R. J. (2013) · Journal of Virology · doi:10.1128/jvi.01361-13 · Cited by 44
Cited by
Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab
Gupta, A., Gonzalez-Rojas, Y., Juarez, E., Crespo Casal, M., Moya, J., Falci, D. R., Sarkis, E., Solis, J., Zheng, H., Scott, N., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107934 · Cited by 1,086
Combination therapy with anti-HIV-1 antibodies maintains viral suppression
Mendoza, P., Gruell, H., Nogueira, L., Pai, J. A., Butler, A. L., Millard, K., Lehmann, C., Suárez, I., Oliveira, T. Y., Lorenzi, J. C. C., et al. (2018) · Nature · doi:10.1038/s41586-018-0531-2 · Cited by 521
Lynch, R. M., Boritz, E., Coates, E. E., DeZure, A., Madden, P., Costner, P., Enama, M. E., Plummer, S., Holman, L., Hendel, C. S., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aad5752 · Cited by 465
Self-citationEffect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption
Bar, K. J., Sneller, M. C., Harrison, L. J., Justement, J. S., Overton, E. T., Petrone, M. E., Salantes, D. B., Seamon, C. A., Scheinfeld, B., Kwan, R. W., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1608243 · Cited by 455
Self-citationSARS-CoV-2 Variants in Patients with Immunosuppression
Corey, L., Beyrer, C., Cohen, M. S., Michael, N. L., Bedford, T., & Rolland, M. (2021) · New England Journal of Medicine · doi:10.1056/nejmsb2104756 · Cited by 437
Metadata
- Authors
- Ko, S.-Y., Pegu, A., Rudicell, R. S., Yang, Z.-Y., Joyce, M. G., Chen, X., Wang, K., Bao, S., Kraemer, T. D., Rath, T., Zeng, M., Schmidt, S. D., Todd, J.-P., Penzak, S. R., Saunders, K. O., Nason, M. C., Haase, A. T., Rao, S. S., Blumberg, R. S., Mascola, J. R., & Nabel, G. J.
- Venue
- Nature
- Published
- 2014-08-13
- Volume
- 514
- Issue
- 7524
- Pages
- 642-645
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2159515958
- Cited by
- 384
- References
- 36
- FWCI
- 14.23
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.